Luka Bočkor

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Simultaneous Determination

Circulating Tumor

Metastatic Colorectal Cancer

Top Venues

Archiv der Pharmazie

International journal of molecular sciences

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Silvio Jakopec, Lejla F Hamzic, Luka Bočkor, Iris Car, Berislav Perić, Srećko I Kirin, Mirela Sedić, Silvana Raić-Malić
Coumarin-modified ruthenium complexes: Synthesis, characterization, and antiproliferative activity against human cancer cells. Archiv der Pharmazie 357 (9) (2024)
Silvio Jakopec, Lejla F Hamzic, Luka Bočkor, Iris Car, Berislav Perić, Srećko I Kirin, Mirela Sedić, Silvana Raić-Malić
Coumarin-modified ruthenium complexes: Synthesis, characterization, and antiproliferative activity against human cancer cells. Archiv der Pharmazie (2024)
Iris Car, Antje Dittmann, Olga Vasieva, Luka Bočkor, Petra Grbčić, Nikolina Piteša, Marko Klobučar, Sandra Kraljević Pavelić, Mirela Sedić
Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro. International journal of molecular sciences 24 (16) (2023)
József Petrik, Donatella Verbanac, Marija Fabijanec, Andrea Hulina-Tomašković, Andrea Čeri, Anita Somborac-Bačura, Roberta Petlevski, Marija Grdić Rajković, Lada Rumora, Božo Krušlin, Mario Štefanović, Neven Ljubičić, Neven Baršić, Antonija Hanžek, Luka Bočkor, Ivana Celap, Alma Demirović, Karmela Barišić
Circulating Tumor Cells in Colorectal Cancer: Detection Systems and Clinical Utility. International journal of molecular sciences 23 (21) (2022)
Lu Turković, Luka Bočkor, Oscar Ekpenyong, Tajana Silovski, Mila Lovrić, Slaven Crnković, Biljana Nigović, Miranda Sertić
Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment. Pharmaceuticals (Basel, Switzerland) 15 (5) (2022)